指南与共识妇科

国家指南实施提高晚期卵巢癌生存率:瑞典全国性SweGCG研究

Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
指南 / 共识 · Gynecol Oncol · 2021-02-10

该研究基于瑞典妇科癌症质量登记库,纳入2008-2011年和2013-2016年FIGO IIIC-IV期原发性上皮性卵巢癌患者,评估首版瑞典国家卵巢癌指南(NGOC)实施前后的手术结局和生存。共纳入3728例,调整年龄和分期后,2013-2016年较2008-2011年生存改善(EMRR 0.89;95%CI 0.82-0.96,p<0.05)。

要点

  • 指南实施后晚期卵巢癌相对生存改善,EMRR 0.89(95%CI 0.82-0.96,p<0.05)。
  • 初治减瘤术(PDS)患者R0率由28.9%升至53.3%,5年相对生存由29.6%升至37.4%。
  • 接受PDS的患者比例由58%降至44%,新辅助化疗+间歇减瘤术(NACT+IDS)R0率由36.8%升至50.1%,但5年相对生存无显著改善。

核心结论

  • 首版瑞典国家卵巢癌指南的实施改善了晚期卵巢癌的相对生存。
  • PDS、R0、年龄≤70岁和IIIC期是相对生存改善的独立因素。

研究设计与样本

  • 基于瑞典妇科癌症质量登记库的全国性 population-based 研究,纳入2008-2011年和2013-2016年FIGO IIIC-IV期原发性上皮性卵巢癌患者。
  • 共纳入3728例,指南实施前1746例,实施后1982例。
  • 计算相对生存和超额死亡率比(EMRR),采用单变量和多变量Poisson回归分析。

主要发现

  • 调整年龄和分期后,2013-2016年较2008-2011年生存改善(EMRR 0.89;95%CI 0.82-0.96,p<0.05)。
  • PDS患者R0率由28.9%升至53.3%(p<0.001),5年相对生存由29.6%(95%CI 26.8-32.8)升至37.4%(95%CI 33.6-41.7),中位生存由35个月(95%CI 32.8-39.2)升至43个月(95%CI 40.9-46.4)。
  • 接受PDS的患者比例由58%降至44%(p<0.001)。
  • NACT+IDS患者R0率由36.8%升至50.1%(p<0.001),但5年相对生存无显著改善(17.5% vs 20.7%,ns)。
  • 与PDS相比,NACT+IDS的EMRR为1.32(95%CI 1.19-1.47,p<0.001),单纯化疗为3.00(95%CI 2.66-3.38,p<0.001)。

关键数值与推荐

  • 指南实施后PDS患者R0率53.3%,5年相对生存37.4%。
  • 指南实施后NACT+IDS患者R0率50.1%,5年相对生存20.7%。
  • PDS、R0、年龄≤70岁和IIIC期是相对生存改善的独立因素。

临床怎么用

  • 晚期卵巢癌应遵循国家指南,优先考虑PDS并追求R0切除以改善生存。
  • 对于选择NACT+IDS的患者,即使R0率提高,生存获益仍不及PDS,需个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The first Swedish National Guidelines for Ovarian Cancer (NGOC) were published in 2012. We aimed to evaluate surgical outcomes and survival in patients with stage IIIC-IV disease, before and after the NGOC implementation. METHOD: Women with primary epithelial ovarian cancer, FIGO stage IIIC-IV, registered in the Swedish Quality Registry for Gynecologic Cancer 2008-2011 and 2013-2016 were included. Surgical outcomes were analyzed, including frequency of complete cytoreduction (R0). Relative survival (RS) and excess mortality rate ratios (EMRRs) were computed as measures of survival. Univariable and multivariable regression (Poisson) were calculated. RESULTS: In total, 3728 women were identified, 1746 before and 1982 after NGOC. After adjusting for age and stage, survival was improved 2013-2016 vs. 2008-2011 (EMRR 0.89; 95%CI:0.82-0.96, p < 0.05). For women undergoing primary debulking surgery (PDS), R0 frequency (28.9% vs. 53.3%; p < 0.001) and 5-year RS (29.6% (95%CI:26.8-32.8) vs. 37.4% (95%CI:33.6-41.7)) were increased, but fewer patients (58% vs. 44%, p < 0.001) underwent PDS after NGOC implementation. Median survival for the PDS cohort increased from 35 months (95%CI,32.8-39.2) to 43 months (95%CI,40.9-46.4). In the neoadjuvant chemotherapy (NACT) + interval debulking surgery (IDS) cohort, R0 increased (36.8% to 50.1%, p < 0.001), but not 5-year RS (17.5% vs. 20.7%, ns). Compared to PDS, the EMRR was 1.32 (95%CI,1.19-1.47, p < 0.001) for NACT+IDS and 3.00 (95%CI,2.66-3.38, p < 0.001) for chemotherapy alone. In multivariable analyses, PDS, R0, age ≤ 70 years, and stage IIIC were found to be independent factors for improved RS. CONCLUSION: Implementation of the first National Guidelines for Ovarian Cancer improved relative survival in advanced ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Dahm-Kähler P, Holmberg E, Holtenman M, et al. Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study. Gynecol Oncol. 2021. PMID: 33581846. doi:10.1016/j.ygyno.2021.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。